Alliance Global Partners analyst Matthew Venezia initiated coverage of Capricor Therapeutics (CAPR) with a Buy rating and $20 price target adding a “Speculative” modifier to its rating, calling ...

INmune Bio Inc. (NASDAQ: INMB) (the 'Company”), a clinical-stage inflammation and immunology company, today announced that it ...

We are delighted to partner with Global Nexus, a distinguished firm with a strong reputation for excellence across the ...